Updates on Fibromyalgia Management

I was recently asked to present something on Fibromyalgia. Since the audience would be colleagues “familiar” with this disease (Rheumas, Rehabs, Neuros), I opted to present updates – the updated definition (which now includes symptoms other than pain and tenderness), the evolution of diagnostic criteria (from 1990 ACR to the latest 2010 ACR), and synthesized some aspects of several guidelines. I had foregone presenting efficacy data on pregabalin, duloxetine and milnacipran because they have already been specifically approved for fibromyalgia – meaning they work and (I feel) there’s no need to add to that. Instead, I presented what fibromyalgia patients experience as far as the two most common drugs used in terms of efficacy and safety. The last slide is actually a reminder why fibromyalgia is difficult to manage – and why the 2012 guidelines had to specify the behavioral “requirements” for those managing fibromyalgia.


Author: Sids Manahan MD 🇵🇭

Rheumatology. Internal Medicine. Educating Patients and Colleagues. Curating Rheumatology. Bloggero-Wanabe.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s